ArticleRespiratory research2026
Cancer risk in patients with pulmonary fibrosis and a rare telomere related gene variant.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRare telomere related gene (TRG) variants are the cause of telomere biology disorders (TBD), a broad spectrum of age-related diseases, such as pulmonary fibrosis (PF) a disease manifesting at older age. TBD patients are at increased risk of certain types of squamous cell carcinomas and hematological malignancies. However, most studies on cancer incidence in TBDs involved relatively young cohorts in which patients with pulmonary fibrosis were underrepresented or absent. Therefore, we investigated cancer incidence in patients with pulmonary fibrosis as major manifestation of TBD (TBD-PF) with a pathogenic (P), likely pathogenic (LP), and variant of unknown significance (VUS) TRG-variant and compared it to the general population.
methodsTBD-PF patients (n = 177) were retrospectively included and cancer history was collected. For each cancer type the observed number of cancers was compared with the expected number adjusted for age and sex based on data of the Netherlands Cancer Registry.
resultsThe TBD-PF cohort (median age 62.8 years, 63% male), consisted of 114 P/LP and 63 VUS carriers. Restricting the analyses to P/LP variant carriers we observed 14 patients with cancer (solid cancer n = 8 (7.0%); hematological cancer n = 6 (5.3%)). The observed all-cancer incidence (12.3%) was comparable to expected (18.9%) in the general population, Observed/Expected incidence 0.6 (95%CI 0.4-1.0). Regarding cancer types, only myelodysplastic syndrome was significantly more frequently observed than expected (Observed/Expected = 56 (95%CI 21–117)). There were no significant differences in clinical characteristics and transplant-free survival between TBD-PF patients with and without cancer. Comparable results were obtained when patients with TRG variants classified as VUS were included.
conclusionAll-cancer risk for TBD-PF patients was comparable to the general population. However, TBD-PF patients have an increased risk of developing myelodysplastic syndrome, underlining the importance of tailored genetic counselling and hematological surveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.